Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

BACKGROUND: The sodium-dependent glucose co-transporter-2 (SGLT2) is expressed in absorptive epithelia of the renal tubules. Remogliflozin etabonate (RE) is the prodrug of remogliflozin, the active entity that inhibits SGLT2. An inhibitor of this pathway would enhance urinary glucose excretion (UGE)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussey, Elizabeth K, Kapur, Anita, O’Connor-Semmes, Robin, Tao, Wenli, Rafferty, Bryan, Polli, Joseph W, James, Charles D, Dobbins, Robert L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682882/
https://www.ncbi.nlm.nih.gov/pubmed/23631443
http://dx.doi.org/10.1186/2050-6511-14-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682882/
https://www.ncbi.nlm.nih.gov/pubmed/23631443
http://dx.doi.org/10.1186/2050-6511-14-25

Ejemplares similares